

Curriculum Vitae
Awewura Kwara, MB.ChB., MPH & TM

PERSONAL INFORMATION

Business address: University of Florida College of Medicine
 Department of Medicine,
 Division of Infectious Diseases and Geographic Medicine
 2055 Mowry Road.
 PO Box 103600
 Gainesville, FL 32610

Telephone Number (352) 273-9501
 Fax Number: (352) 273-9275
 Electronic Mail Address awewura.kwara@medicine.ufl.edu

EDUCATION

Medical School MB. ChB., University of Ghana Medical School, Accra, Ghana,
 1986-92

Other Degrees MPH & TM, Tulane University School of Public Health and
 Tropical Medicine, New Orleans, LA, 2000-01

POSTGRADUATE TRAINING

Residency Intern and Resident, Internal Medicine, Cook County Hospital,
 Chicago, IL, 1996-99

Fellowship Infectious Diseases, Tulane University School of Medicine, New
 Orleans, LA, 1999-2001

POSTGRADUATE HONORS AND AWARDS

2001 - 2002 Wetmore Foundation Fellowship for Tuberculosis/HIV

2013 Master of Arts *ad eundem* degree, Brown University

2016 Fellow of the Infectious Diseases Society of America (FIDSA)

BOARD CERTIFICATION

1999 Diplomate, American Board on Internal Medicine
 (Re-certified 2009)

2001 Diplomate, American Board of Infectious Diseases

(Re-certified 2011)

PROFESSIONAL LICENSES

| | |
|----------------|---------------------------|
| 1996 – 1999 | Illinois (# 036-098705) |
| 1999 – 2002 | Louisiana (# 13119R) |
| 2002 – 2016 | Rhode Island (# MD 10814) |
| 2016 – Present | Florida (# ME 127542) |

ACADEMIC APPOINTMENTS

| | |
|--------------|---|
| 2001-2002 | Clinical Instructor in Medicine, Tulane University School of Medicine |
| 2002-2003 | Clinical Instructor, Warren Alpert Medical School of Brown University |
| 2003-2012 | Assistant Professor of Medicine, Warren Alpert Medical School of Brown University |
| 2012-2016 | Associate Professor of Medicine, Warren Alpert Medical School of Brown University |
| 2016-present | Associate Professor of Medicine, University of Florida College of Medicine |

HOSPITAL APPOINTMENTS

| | |
|--------------|--|
| 2002-2016 | Staff Physician, The Miriam Hospital |
| 2002-2016 | Staff Physician, Rhode Island Hospital |
| 2003-2006 | Staff Physician, Landmark Hospital |
| 2009 -2016 | Consulting staff, Women and Infants Hospital of Rhode Island |
| 2015-2016 | Medical Director, Tuberculosis Clinic, The Miriam Hospital |
| 2016-present | Active Staff Physician, UF Health/Shands Hospital |

OTHER APPOINTMENTS

| | |
|---------|--|
| 1994-95 | Medical Officer, Korle-Bu Teaching Hospital, Accra, Ghana |
| 1995-96 | Medical Officer, Medical Research Council Laboratories, Fajara, Gambia |
| 2001-02 | Member, Infection Control Committee, Charity Hospital, New Orleans, LA |
| 2005-06 | Member, Opportunistic Infections Subcommittee, AIDS Clinical Trials Group (ACTG), NIH |
| 2006-07 | Member, Tuberculosis Working Group, ACTG, NIH |
| 2007 | Grant Reviewer, Canadian Institute of Health Research |
| 2008 | Ad hoc Grant reviewer, Center for Scientific Review, Fogarty International Center, NIH |
| 2009- | Member, Inter-CFAR HIV/TB Working Group |
| 2010- | Invited abstract Reviewer, AIDS 2010 Conference |
| 2011-13 | Editorial Board Member, Journal of Pharmacogenomics and |

| | |
|---------|---|
| | Pharmacoproteomics |
| 2011 | Co-Director, International Program, Lifespan/Tufts/Brown Center for AIDS Research (CFAR) |
| 2011-14 | Member, Tuberculosis Transformative Science Group, ACTG, NIH |
| 2014 | Grant reviewer, Special Emphasis Panel, ZRG1 AIDS and AIDS-Related Research (AARR) Integrated Review Group, NIH |
| 2014-20 | Member, AIDS Discovery and Development of Therapeutics (ADDT) Study Section, NIH |
| 2010- | Invited abstract Reviewer, Union World Conference on Lung Health |

MEMBERSHIP IN SOCIETIES

| | |
|-----------|---|
| 2001- | American College of Physicians |
| 2001-2009 | American Society of Tropical Medicine and Hygiene |
| 2002- | Infectious Diseases Society of America |
| 2003- | American Society of Microbiology |
| 2012- | International Union Against Tuberculosis and Lung Disease |

ORIGINAL PUBLICATIONS IN PEER-REVIEWED JOURNALS

1. **Kwara A**, Adegbola RA, Corrah PT, Weber M, Achtman M, Morelli G, Caugant DA, Greenwood BM. Meningitis caused by a serogroup W-135 clone of the ET-37 complex of *Neisseria meningitidis* in West Africa. *Tropical Medicine and International Health* 1998; 3:742-746.
2. Weber MW, Milligan P, Giadom B, Pate MA, **Kwara A**, Sadiq AD, Chanayireh M, Whittle H, Greenwood BM, Mulholland K. Respiratory illness after severe *Respiratory syncytial virus* infection in infancy in the Gambia. *J Pediatr* 1999;135:683-8.
3. **Kwara A**, Schiro R, Cowan LS, Hyslop NE, Wisner MF, Roahen Harrison S, Kissinger P, Diem L, Crawford JT. Evaluation of the epidemiologic utility of secondary typing methods for differentiation of *Mycobacterium tuberculosis* isolates. *J Clin Microbiol* 2003;41:2683-2685.
4. **Kwara A**, Carter EJ, Rich JD, Flanigan TP. Development of opportunistic infections after diagnosis of active tuberculosis in HIV-infected patients. *AIDS Patient Care and STDS* 2004;18:341-347.
5. **Kwara A**, Flanigan TP, EJ Carter. Highly active antiretroviral therapy (HAART) in adults with tuberculosis: current status. *Int J Tuberc Lung Dis* 2005;9:248-257.
6. **Kwara A**, Roahen Harrison S, Prystowsky E, Kissinger P, Mathison J, Adams R, Hyslop NE. Manifestations and outcome of extrapulmonary tuberculosis: impact of human immunodeficiency virus coinfection. *Int J Tuberc Lung Dis* 2005;9:485-493.
7. **Kwara A**, DeLong A, Rezk N, Hogan J, Burtwell H, Chapman S, Moreira CC, Kurpewski J, Ingersoll J, Caliendo AM, Kashuba A, Cu-Uvin S. Antiretroviral Drug Concentrations and Virologic Rebound in the Genital Tract of HIV-Infected Women on Chronic HAART
Antiretroviral Drug Concentrations and Virologic Rebound in the Genital Tract of HIV-Infected Women on Chronic HAART. *Clin Infect Dis* 2008;46:719-725.

8. **Kwara A**, Herold JS, Machan JT, Carter EJ. Factors Associated with Failure to Complete Isoniazid Treatment for Latent Tuberculosis Infection in Rhode Island. *Chest* 2008;133:862-868.
9. **Kwara A**, Lartey M, Sagoe KW, Xexemeku F, Kenu E, Oliver-Commey J, Boima V, Sagoe A, Boamah I, Greenblatt DJ, Court MH. Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation. *J Clin Pharmacol* 2008;48:1032-1040.
10. Nijhawan AE, Zachary AC, **Kwara A**, Venna N. Status epilepticus resulting from severe efavirenz toxicity in an HIV-infected patient. *AIDS Read* 2008;18:386-388.
11. **Kwara A**, Lartey M, Sagoe KW, Rezk N, Court MH. CYP2B6 (c.516G→T) and CYP2A6 (*9B and/or *17) Polymorphisms are Independent Predictors of Efavirenz Plasma concentrations in HIV-infected Patients. *Br J Clin Pharmacol* 2009; 67:427-436.
12. **Kwara A**, Lartey M, Boamah I, Rezk N, Oliver-Commey J, Kenu E, Kahusba ADM, Court MH. Pharmacokinetics of NRTIs in TB/HIV co-infected patients: The UGT2B7*1c haplotype tagSNP c.735A>G is associated with higher zidovudine glucuronidation. *J Clin Pharmacol* 2009;49:1079-1090.
13. **Kwara A**, Lartey M, Sagoe WC, Kenu E, Court MH. CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patients. *AIDS* 2009;23:2101-6.
14. **Kwara A**, Ramachandran G, Swaminathan S. Dose adjustment of the nonnucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all. *Expert Opin Drug Metab Toxicol* 2010;6:55-68.
15. Forson A, Kudzawu S, **Kwara A**, Flanigan TP. Pattern of *Mycobacterium tuberculosis* Drug Resistance among Chronic Pulmonary Tuberculosis Patients at a Tertiary Hospital in Ghana. *Ghana Med J*, 2010;44:42-46.
16. Howley IW, Lartey M, Machan JT, Obo-Akwa A, Flanigan TP, Talbot EA, **Kwara A**. Highly active antiretroviral therapy and employment status in Accra, Ghana. *Ghana Med J* 2010;44:144-149.
17. **Kwara A**, Shah D, Renner LA. Reasons for and outcome of hospital admissions in HIV-infected children at the Korle Bu Teaching Hospital Accra, Ghana. *West Afri J Med* 2010;29:379-83.
18. **Kwara A**, Lartey M, Sagoe KW, Court MH. Paradoxically Elevated Efavirenz Concentrations in HIV/TB Co-infected Patients with CYP2B6 516TT Genotype on Rifampin-containing Antituberculous Therapy (Research Letter). *AIDS* 2011;25:388-390.
19. Lartey M, Sagoe K, Kenu E, Oliver-Commey J, Bioma V, Makafui S, Mingle JAA, Machan J, **Kwara A**. Plasma HIV RNA Dynamics in Response to Efavirenz-based HAART in HIV/TB Co-infected compared to HIV-Mono-infected Patients. *Clin Infect Dis* 2011;52:547-550.

20. Vanhomwegen J, **Kwara A**, Martin M, Gillani F, Muntungi P, Crellin J, Obaro S, Hart C, Carter EJ, Rastogi N. Impact of immigration on the molecular epidemiology of tuberculosis in Rhode Island *J Clin Microbiol* 2011;49:834-44.
21. **Kwara A**, Tashima K, Poethke P, Kurpewski J, Kashuba ADM, Court M. Modest but variable effects of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African American and Caucasian Volunteers. *Antimicrob Agents Chemother* 2011;55:3527-3533.
22. Burton NT, Forson A, Lurie MN, Kudzawu S, Kwarteng E, **Kwara A**. Factors associated with mortality among patients with tuberculosis attending a Teaching Hospital Clinic in Accra, Ghana. *Trans R Soc Trop Med Hyg* 2011;105:3527-33.
23. Temple B, **Kwara A**, Sunesara I, Mena L, Dobbs T, Henderson H, Holcomb M, Webb R. Factors associated with recently transmitted Mycobacterium tuberculosis strain MS0006 in Hinds County, Mississippi. *South Med J*. 2011;104:819-826.
24. Haas DW, Kuritzkes DR, Ritchie MD, Amur S, Gage BF, Maartens G, Masys D, Fellay J, Phillips E, Ribaud HJ, Freedberg KA, Petropoulos C, Manolio TA, Gulick RM, Haubrich R, Kim P, Dehlinger M, Abebe R, Telenti A; Workshop Pharmacogenomics-A Path Towards Personalized HIV Care. Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases. *HIV Clin Trials*. 2011;12:277-85.
25. Renner L, Ghebremichael M, Goka P, Lartey M, **Kwara A**, Paintsil E. Predictors of the trends in absolute and percentage CD4+ T-lymphocyte in HIV-infected children in Ghana. *Int J Infect Dis* 2011;6:7-15.
26. Carten M, Kiser J, **Kwara A**, MaWhinney S, Cu-Uvin S. Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B®), and Efavirenz. *Infect Dis Obst Gyne* vol. 2012, Article ID 137192, 4 pages, 2012. doi:10.1155/2012/137192.
27. Wilhelm AK, Paci G, Lartey M, **Kwara A**. Treatment default among patients initiating HAART at the Korle-Bu Teaching Hospital in Accra, Ghana. *West Afr J Med* 2012;31:264-9.
28. **Kwara A**, Cao L, Yang H, Poethke P, Kurpewski J, Tashima KT, Mahjoub BD, Court MH, Peloquin CA. Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance. *Pharmacotherapy* 2014; 34:265-71.
29. Haas DW, **Kwara A**, Richardson DM, Baker P, Papageorgiou I, Acosta EP, Morse GD, Court MH. Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes. *J Antimicrob Chemother* 2014;69:21-75-82.
30. Court MH, Almutairi F, Greenblatt D, Hazarika S, Sheng H, Klein K, Zanger U, Bourgea J, Patten C, **Kwara A**. Isoniazid mediates the CYP2B6*6 genotype-dependent interaction

between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6. *Antimicrob Agents Chemother* 2014;58:4145-4152.

31. Adjei AA, Brandful J, Lurie M, Lartey M, Krampa F, **Kwara A**, Adiku TK, Tettey Y, Gyasi RK, Lawson AL, Flanigan T. Human immunodeficiency virus, syphilis prevalence and risk factors among migrant workers in Konongo, Ghana. *Advances Infect Dis* 2014;4:132-141.
32. Yawson AE, Appiah LK, Yawson AO, Bonsu G, Aluze-Ele S, Owusu Amanhyia N, Lartey M, Adjei AA, Lawson AL, Beckwith C, **Kwara A**, Flanigan T. Sex differences in perceived risk and testing experience of HIV in an urban fishing setting in Ghana. *Int J Equity Health* 2014;13:109.
33. Montague BT, Comella J, Alexander-Scott NE, Bandy U, **Kwara A**. Tuberculosis control in RI: maintaining control efforts in the context of declining incidence and funding for tuberculosis programs. *R I Med J* 2014;98:18-21.
34. Reece R, Norman B, **Kwara A**, Flanigan T, Rana A. Retention to care of HIV-positive postpartum females in Kumasi, Ghana. *J Int Assoc Provid AIDS Care* 2015 Aug 28. pii: 2325957415603507 [Epub ahead of print].
35. Kumar N, Reece R, Norman B, **Kwara A**, Flanigan T, Rana A. Delayed entry to care by men with HIV infection in Kumasi, Ghana. *Pan African Med J* 2015;22:107.
36. Brown AN, Drusano GL, Adams JR, Rodriquez JL, Jambunathan K, Baluya DL, Brown DL, **Kwara A**, Hafner R, and Louie A. Preclinical Evaluations to Identify Optimal Linezolid Regimens for Tuberculosis Therapy. *mBio* 2015;6(6). Pii:e01741-15. PMID: PMC4631805.
37. Enimil A, Nugent N, Amoah C, Norman B, Antwi S, Ocran J, **Kwara A**, Barker DH. Quality of Life among Ghanaian Adolescents Living with Perinatally Acquired HIV: A Mixed Methods Study. *AIDS Care* 2016;28:460-4.
38. Nassikas N, Forson A, Yang H, Kwarteng E, **Kwara A**. Predictors of mortality in patients with extrapulmonary tuberculosis. *Ghana Med J* 2015;49:233-8.
39. Congdon M, Gjelsvik A, Lurie M, Enimil A, Antwi S, **Kwara A**. Role of nutritional status on follow-up among HIV-infected children at a Teaching Hospital clinic in Ghana. *West Afr J Med* 2015;34:20-6.
40. Archampong TN, Lartey M, Sagoe KW, Obo-Akwa A, Kenu E, Gillani FS, Yang H, Boamah I, Flanigan T, **Kwara A**. Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients. *BMC infect Dis* 2016 Jan 13;16(1):14.doi: 10.1186/s12879-016-1342-4.
41. Archampong TN, Boyce CL, Lartey M, Sagoe KW, Obo-Akwa A, Kenu E, Blackard JT, **Kwara A**. HBV genotypes and drug resistance mutations in antiretroviral treatment-naïve and treatment-experienced HBV-HIV-coinfected patients. *Antivir Ther* 2016 May 11. doi: 10.3851/IMP3055. [Epub ahead of print].

42. **Kwara A**, Enimil A, Gillani FS, Yang H, Sarfo A, Dompok A, Ortsin A, Osei-Tutu L, Kwarteng Owusu S, Wiesner L, Norman J, Kurpewski J, Peloquin CA, Ansong D, Antwi S. Pharmacokinetics of First-line Antituberculosis Drugs Using WHO Revised Dosage in Children with Tuberculosis with and without HIV Coinfection. *J Pediatric Infect Dis Soc* 2016;5:356-365.
43. Gehre F, Otu J, Kendall L, Forson A, **Kwara A**, Kudzawu S, Kehinde AO, Adebisi O, Salako K, Baldeh I, Jallow A, Jallow M, Dagnra A, Dissé K, Kadanga EA, Idigbe EO, Onubogu C, Onyejebu N, Gaye-Diallo A, Ba-Diallo A, Rabna P, Mane M, Sanogo M, Diarra B, Dezemon Z, Sanou A, Senghore M, Kwambana-Adams BA, Demba E, Faal-Jawara T, Kumar S, Tientcheu LD, Jallow A, Ceesay S, Adetifa I, Jaye A, Pallen MJ, D'Alessandro U, Kampmann B, Adegbola RA, Mboup S, Corrah T, de Jong BC, Antonio M. The emerging threat of pre-extensively drug-resistant tuberculosis in West Africa: preparing for large-scale tuberculosis research and drug resistance surveillance. *BMC Med* 2016 Nov 3;14(1):160.
44. Ankomah A, Ganle JK, Lartey MY, **Kwara A**, Nortey PA, Okyerefo MP, Laar AK. ART access-related barriers faced by HIV-positive persons linked to care in southern Ghana: a mixed method study. *BMC Infect Dis* 2016 Dec 7;16(1):738
45. Antwi S, Yang H, Enimil A, Sarfo AM, Gillani FS, Ansong D, Dompok A, Orstin A, Opoku T, Bosomtwe D, Wiesner L, Norman J, Peloquin CA, **Kwara A**. Pharmacokinetics of the First-line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with and without HIV Coinfection. *Antimicrob Agents Chemother* 2017 Jan 24;61(2). pii: e01701-16. doi: 10.1128/AAC.01701-16.
46. Sam-Agudu NA, Paintsil E, Aliyu MH, **Kwara A**, Ogunsola F, Afrane YA, Onoka C, Awandare GA, Amponsah G, Cornelius LJ, Mendy G, Sturke R, Ghansah A, Siberry GK, Ezeanolue EE. Building sustainable local capacity for global health research in West Africa. *Ann Glob Health* 2016 Nov - Dec ;82(6):1010-1025.
47. Boyce CL, Ganova-Raeva L, Archampong TNA, Lartey M, Sagoe KW, Obo-Akwa A, Kenu E, **Kwara A**, Blackard JT. Identification and comparative analysis of hepatitis B virus genotype D/E recombinants in Africa. *Virus Genes*. 2017 May 31. doi: 10.1007/s11262-017-1469-4. [Epub ahead of print].
48. Laar AK, **Kwara A**, Nortey PA, Ankomah AK, Okyerefo MPK, Lartey MY. Use of non-prescription remedies by Ghanaian human immunodeficiency virus-positive persons on antiretroviral therapy. *Front Public Health*. 2017 May 26;5:115. doi: 10.3389/fpubh.2017.00115. eCollection 2017.
49. Saavedra A, Campinha-Bacote N, Hajjar M, Lartey M, Gillani F, Obo-Akwa A, Kenu E, Kwara A. Causes of Death and Factors Associated with Early Mortality of HIV-infected Adults Admitted to Korle-Bu Teaching Hospital *Pan African Med J* 2017; 27:48 doi:10.11604/pamj.2017.27.48.8917.
50. Yang H, Enimil A, Gillani FS, Antwi S, Dompok A, Ortsin A, Adu Awhireng E, Owusu M, Wiesner L, Peloquin CA, Kwara A. Evaluation of the Adequacy of the 2010 Revised World Health Organization Recommended Dosages of the First-line Antituberculosis Drugs for Children. *Pediatr Infect Dis Journal* 2017 (accepted).

51. Cao L, Greenblatt DJ, **Kwara A**. Inhibitory effects of selected antituberculosis drugs on common human hepatic cytochrome P450 and UDP-glucuronosyltransferase enzymes. *Drug Metabolism and Disposition* 2017 (accepted).

OTHER PEER-REVIEWED PUBLICATIONS

1. **Kwara A**, Feldman S, DeJace PM, Hyslop Jr. NE. An AIDS patient with buttock and thigh swelling. *Infect Med* 2001;18:84-88.
2. **Kwara A**, Pappas PG, Hasbun R, Beilke MA. A lawyer from Honduras with fever and hypotension. *Infect Med* 2001;18:453-4.
3. Ramgoolam A, **Kwara A**, Silio M. A neonate with meningitis. *Infect Med* 2003;20:330-332.
4. **Kwara A** (2012). Towards Individualized HIV Therapy: Pharmacogenetic-guided Clinical Trials are Needed Now. *J Pharmacogenom Pharmacoproteomics* 3:e116.doi:10.4172/2153645.1000e116

BOOKS AND BOOK CHAPTERS

1. **Kwara, A**. Infectious Diarrhea. In: *Andreoli & Carpenter's Cecil Essentials of Medicine*, 9th Edition, Chapter 96, pp. 899-904, Elsevier Publishing, Philadelphia, Pennsylvania, 2015.

PUBLICATIONS SUBMITTED OR IN PREPARATION

1. Forson A, **Kwara A**, Kudzawu S, Omari M, Ganu H, Aborgah A, Baddoo A, Out J, Gehre F, de Jong B, Antonio M. Tuberculosis Drug-Resistance among Previously Treated Patients in Ghana: Implications for MDR TB Therapy (submitted to BMC Infect Dis).
2. Dompreeh A, Tang X, Zhou J, Adu Ahwireng E, Topletz A, Antwi S, Enimil A, Langae T, Court MH, Kwara A. Pharmacogenetics of isoniazid and rifampin pharmacokinetics in Ghanaian children with tuberculosis (in preparation).

ABSTRACTS

1. **Kwara A**, Roahen Harrison S, Prystowsky E, Kissinger P, Mathison J, Hyslop NE. Extrapulmonary tuberculosis: A 9-year review of experience in metropolitan New Orleans. Poster presented at Infectious Disease Society of America (IDSA) meeting, Chicago, October 2002 [abstract 669].
2. **Kwara A**, Schiro R, Cowan LS, Hyslop NE, Wiser MF, Roahen Harrison S, Kissinger P, Diem L, Crawford JT. Evaluation of the epidemiologic utility of secondary typing methods for differentiation of *Mycobacterium tuberculosis* isolates. Poster presented at American Thoracic Society (ATS) International Meeting, Seattle, May 2003 [abstract page A609].

3. Roahen Harrison S, **Kwara A**, Schiro R, Wiser MF, Kissinger P, Ratard R, Degraw C, Fernandez M, Jones C, Hyslop NE. Epidemiological risk factors associated with *Mycobacterium tuberculosis* clusters in metropolitan New Orleans. Oral presentation at the American Thoracic Society (ATS) International Meeting, Seattle, May 2003. [abstract page A433].
4. **Kwara A**, Martin M, Gillani F, Mutungi P, Obaro S, Machan J, Crellin J, Gosciminski M, Carter EJ. Missed Opportunities for Tuberculosis Elimination: Lessons from Rhode Island. Poster presented at American Thoracic Society (ATS) International Meeting, Seattle, May 2007 [abstract page A392].
5. Herold J, Machan J, Carter EJ, **Kwara A**. Factors Associated with Latent TB Treatment Outcome in Rhode Island (RI). Poster presented at American Thoracic Society (ATS) International Meeting, San Francisco, May 2007 [abstract page A465].
6. **Kwara A**, DeLong A, Rezk N, Hogan J, Burtwell H, Chapman S, Moreira CC, Kurpewski J, Ingersoll J, Caliendo AM, Kashuba A, Cu-Uvin S. Antiretroviral Drug Concentrations in the Genital Tract of HIV-Infected Women. Infectious Disease Society of Obstetrics and Gynecology 34th Annual Scientific Meeting, August 9 to 11, 2007, Boston, MA (Oral Presentation).
7. **Kwara A**, Lartey M, Sagoe K, Oliver-Commey J, Kenu E, Xexemeku F, Boimah V, Sagoe A, Flanigan T, Greenblatt DJ, Court MH. Frequency of Functional CYP2B6 Variants in Ghanaian TB/HIV Co-infected Patients: Implications for Efavirenz-based Antiretroviral Therapy. First College of Health Sciences Annual Scientific Conference, Accra, Ghana, September 26–28, 2007 (Oral Presentation).
8. Lartey M, Sagoe K, Oliver-Commey J, Kenu E, Xexemeku F, Boimah V, Sagoe A, Flanigan T, **Kwara A**. Clinical and Immunological Outcome of Efavirenz-based Therapy in TB/HIV Co-infected Patients at Korle-Bu Teaching Hospital. First College of Health Sciences Annual Scientific Conference, Accra, Ghana, September 26–28, 2007 (Oral Presentation).
9. Howley IW, Lartey M, Machan JT, Obo-Akwa A, Flanigan TP, Talbot E, **Kwara A**. The Effect of Highly Active Antiretroviral Therapy on Employment, Accra, Ghana. Poster presented at Infectious Diseases Society of America (IDSA) Annual Meeting, Washington DC, September 2008 [abstract # 2977].
10. **Kwara A**, Lartey M, Boamah I, Rzek N, Oliver-Commey J, Kenu E, Kashuba A, Court M. Variability in the pharmacokinetics of NRTI in TB/HIV Ghanaian patients. Poster presented at 16th Conference on Retroviruses and Opportunistic Infections (CROI 2009), Montreal Canada, February 8-11, 2009 [abstract #699].
11. Carten ML, Kissner J, **Kwara A**, Ma Whinney S, Cu-Uvin S. Pharmacokinetic (PK) interactions between the hormonal emergency contraception plan B® (levonorgestrel) and efavirenz (EFV). Poster presented at 16th Conference on Retroviruses and Opportunistic Infections (CROI 2010), San Francisco, February 16-19, 2010. [abstract # U-115].
12. **Kwara A**, Tashima K, Poethke P, Kurpewski J, Kashuba ADM, Court M. Modest but variable effects of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy

- African American and Caucasian Volunteers. Poster presented at 39th ACCP Annual Meeting, Baltimore, September 12-14, 2010 [abstract #66].
13. Temple B, **Kwara A**, Sunesara I, Mena L, Webb R. The emergence of the MS0006 TB Strain and its Effects on the Homeless and HIV-infected Population of County X in Mississippi. Poster presented at 48th Infectious Diseases Society of America (IDSA) Annual Meeting, Vancouver, Canada, October 21-24, 2010 [abstract # 1295].
 14. Wilhelm A, Paci G, Lartey M, **Kwara A**. Treatment default is low among patients initiating HAART at the Korle-Bu Teaching Hospital Clinic in Accra, Ghana. Poster presented at 59th American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting, Atlanta, Georgia, November 3-7, 2010 [abstract # 674].
 15. **Kwara A**, Yang H, Lartey M, Sagoe K, Court MH. Identification of HIV-infected Ghanaian patients with low and high efavirenz plasma mid-dose concentrations. Poster presented at 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Rome, Italy, July 17-20 2011 [abstract # MOPE 198].
 16. Temple B, Sunesara I, **Kwara A**, Dobbs T, Holcomb M, Webb R. Transmission of HIV and non-HIV TB cases in Mississippi: Intensified Efforts are needed among African Americans and HIV-infected sub-populations. Poster presented at 49th Infectious Diseases Society of America (IDSA) Annual Meeting, Boston, Massachusetts, October 20-23, 2011 [abstract # 995].
 17. Court MH, Almutairi FE, Greenblatt DJ, Duan SX, Klein K, Zanger UM, and **Kwara A**. Identification of Isoniazid as a Potent Inhibitor of CYP2A6-mediated Efavirenz 7-hydroxylation in CYP2B6*6 Genotyped Human Liver Microsomes. Poster presented at 19th Conference on Retroviruses and Opportunistic Infections (CROI 2013), Atlanta, February 28-March 6, 2013 [abstract # 517].
 18. **Kwara A**, Lartey M, Kenu E, Mahjoub B, Peloquin CA. Isoniazid, rifampin and pyrazinamide pharmacokinetics in Ghanaian HIV-TB co-infected patients. 44th Union World Conference on Lung Health, Paris, October 30 - November 3 2013 [Oral presentation, # OP-198-02].
 19. Haas DW, **Kwara A**, Richardson DM, Baker P, Papageorgiou I, Acosta EP, Morse GD, Court MH and the AIDS clinical Trial Group (ACTG). Contribution of CYP2A6, UGT2B7, and other NON-CYP2B6 Polymorphisms to Plasma efavirenz Exposure. Poster presented at 20th Conference on Retroviruses and Opportunistic Infections (CROI 2014), Boston, March 3-6, 2014 [abstract # 506].
 20. **Kwara A**, Enimil A, Gillani F, Yang H, Dompok A, Ortsin A, Sarfo A, Topletz A, Wiesner L, Ansong D, Antwi S, and Ghana Pediatric PK Study Group. Pharmacokinetics of First-line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with and without HIV Coinfection. Poster presented at 20th international AIDS Conference (AIDS 2014), Melbourne, Australia, July 20-25, 2014 [Poster # TUPE027].

21. Kudzawu S, Omari M, Forson A, Baddoo A, Ganu H, De Jong BC, Out J, **Kwara A**, Antonio M. First- and second-line Mycobacterium tuberculosis resistance at a tertiary hospital chest clinic in Ghana. 46th Union World Conference on Lung Health, Cape Town, South Africa. December 2 – 6 2015. [Poster # PC-1223-06].
22. Tang X, Dompseh A, Zhou J, Topletz, Ahwireng E, Antwi S, Court M, **Kwara A**. Four-SNP NAT2 genotyping panel identifies slow but not rapid isoniazid metabolizer phenotype in Ghanaian children with tuberculosis. 46th Union World Conference on Lung Health, Cape Town, South Africa. December 2 – 6 2015. [Poster # PC-1085-08].
23. Enimil A, Gillani F, Sarfo A, Bosumtwe D, Opoku T, Badu-Peprah, Antwi S, **Kwara A**. Impact of HIV co-infection on the clinical presentation of childhood tuberculosis in Ghanaian children. 46th Union World Conference on Lung Health, Cape Town, South Africa. December 2 – 6 2015. [Poster, #PC-907-04].
24. **Kwara A**, Enimil E, Yang H, Gillani F, Dompseh A, Orstin A, Wiesner L, Antwi S. Pharmacokinetics of first-line anti-tuberculosis drugs in children with tuberculosis with and without HIV coinfection. 46th Union World Conference on Lung Health, Cape Town, South Africa. December 2 – 6 2015. [Oral presentation, # OA-424-05].
25. **Kwara A**, Yang H, Enimil A, Sarfo AM, Ansong D, Gillani FS, Dompseh A, Orstin A, Opoku T, Bosumtwe D, Wiesner L, Norman J, Peloquin CA, Antwi S. Impact of HIV infection on the pharmacokinetics of four first-line antituberculosis drugs in children with tuberculosis in Ghana. Poster presented at 21st International AIDS Conference (AIDS 2016), Durban, South Africa, July 18 – 22, 2016 [Poster # TUPEB084].

INVITED PRESENTATIONS

1. New Orleans Citywide Infectious Diseases Meeting, New Orleans, Louisiana, March 8, 2002, “Extrapulmonary tuberculosis: 9-Years experience in metropolitan New Orleans.”
2. ACTG Scientific Meeting, New Orleans, Louisiana, April 4, 2002, “Molecular epidemiology of tuberculosis transmission in Louisiana Public Health Region 1, 1999-2001.”
3. Grand Rounds, Landmark Medical Center, Woonsocket, Rhode Island, December 16, 2002, “Natural history of human immunodeficiency virus (HIV) infection: implications for early intervention.”
4. Brown University AIDS Clinical Taskforce Meeting, Providence, Rhode Island, January 9, 2003, “Human immunodeficiency virus (HIV) and tuberculosis co-infection.”
5. Family Practice Grand Rounds, Memorial Hospital, Pawtucket, Rhode Island, February 6 2003, “Targeted tuberculin testing and treatment of latent TB infection.”
6. Infectious Diseases Conference, Rhode Island Hospital, September 15, 2004, “Highly active antiretroviral therapy (HAART) in patients with tuberculosis.”

7. Department of Medicine, University of Ghana Medical School, Accra, Ghana. September, 24 2004, "Highly active antiretroviral therapy (HAART) in patients with tuberculosis."
8. Family Practice Grand Rounds, Memorial Hospital, Pawtucket, Rhode Island, January 13 2005, "Targeted tuberculin testing and treatment of latent TB infection."
9. Infectious Diseases Lecture Series, UMass Memorial Medical Center, Worcester, MA. May 6, 2005, "Management of TB and HIV coinfection."
10. Family Resources Community Action, Woonsocket, RI, July 19, 2005, "Infection control for Health Care Personnel,"
11. Infectious Diseases Lecture Series, The Miriam Hospital, Providence, RI, September 21, 2006, "Rifampin and Antiretroviral drug Interactions: Implication for Concurrent Therapy."
12. Research Seminar, Medical Research Council Laboratories, Fajara, Gambia, November 20, 2006, "Rifampin and Antiretroviral drug Interactions: Implication for Concurrent Therapy."
13. Lifespan/Tufts/Brown CFAR seminar, March 30, 2007, "Response to Efavirenz-based HAART in TB/HIV Co-infected Patients receiving Rifampin-containing TB treatment in Ghana."
14. Scholarly Concentration on Global Health, Brown University, Providence, RI, April 3, 2007, "Staying Healthy While Traveling Abroad."
15. CODAC Behavioral Healthcare of Cranston, RI, May 30, 2007, "Targeted Tuberculin Testing and Treatment of Latent TB Infection."
16. Primary Care Provider Course on HIV Medicine, The Miriam Hospital, Providence, RI, July 16-18, 2007, "HIV and TB."
17. Update on HIV/TB Co-infection: Management and Diagnostics. Accra & Kumasi, Ghana, September 19 & 21, 2007, "Treatment of tuberculosis and HIV co-infection."
18. Update on HIV/TB Co-infection: Management and Diagnostics. Accra & Kumasi, Ghana, September 19 & 21, 2007, "Management of multi-drug resistant (MDR) tuberculosis."
19. Lifespan/Tufts/Brown CFAR seminar, The Miriam Hospital, Providence, RI, March 14, 2008, "Pharmacokinetics and Safety of Efavirenz in the Presence of Rifampin in TB/HIV Co-infected Persons: Pharmacogenetic effect of CYP2B6 variation."
20. Infectious Diseases Conference, The Miriam Hospital, Providence, RI, March 19, 2008, "The Pharmacogenetics of Efavirenz Therapy."
21. Unite for Sight Fifth Annual International Health Conference, Yale University, New Haven, CT, April 12, 2008, "Tuberculosis and HIV research at the Korle-Bu Teaching Hospital."
22. CODAC Behavioral Healthcare of Cranston, RI, April 30, 2008, "Targeted Tuberculin Testing and Treatment of Latent TB Infection."

23. SNMA Region VII Annual Conference, December 6, 2008, "The HIV/TB Co-Epidemic: Is the Global response Adequate?"
24. TB: Here and Now: Annual New England Clinicians Conference, Newport, RI, May 1, 2010, "Management of HIV/TB Co-infection."
25. Fourth Annual New England TB Symposium, Broad Institute, Boston, MA, July 16, 2010, "Understanding the drug-drug interactions between the NNRTIs and rifampin-containing tuberculosis therapy."
26. Program in Pharmacology and Experimental therapeutics and Program in Cellular and Molecular Physiology Joint Program Seminar, Boston, MA, November 16, 2010, "Drug-drug interactions between efavirenz and rifampin: understanding inter-individual variability."
27. Immunology Conference, The Miriam Hospital, Providence, RI, February 23, 2011. "Management of HIV in TB co-infected Patients."
28. Infectious Diseases Lecture Series, The Miriam Hospital, Providence, RI, February 24, 2011, "Drug-drug interactions between the NNRTIs and rifampin-containing TB therapy."
29. Sub-Saharan Africa CFAR Conference, Serena Hotel, Kampala, Uganda, May 27, 2011, Panel presentation: "Challenges to controlling HIV-associated TB in sub-Saharan Africa."
30. Ghana College of Physicians and Surgeons/West African College of Physicians: Update in Infectious Diseases, Accra, Ghana, June 28, 2011, "Update on the management of HIV/TB co-infection."
31. Ghana College of Physicians and Surgeons/West African College of Physicians: Update in Infectious Diseases, Accra, Ghana, June 28, 2011, "Update on the management of MDR/XDR TB."
32. Ghana College of Physicians and Surgeons/West African College of Physicians: Update in Infectious Diseases, Accra, Ghana, June 29, 2011, "Research proposal writing."
33. University of Ghana College of Health Sciences Faculty Development Workshop, Accra, Ghana, September 20, 2011, "Overview of developmental grants under USAID/HED-funded project and other opportunities."
34. Ghana College of Physicians and Surgeons Medical Knowledge Fiesta 2012, Accra, Ghana, August 8, 2012, "HIV treatment update."
35. Ghana College of Physicians and Surgeons Medical Knowledge Fiesta 2012, Accra, Ghana, August 8, 2012, "HIV and tuberculosis co-infection update."
36. Ghana College of Physicians and Surgeons Medical Knowledge Fiesta 2013, Golden Tulip Hotel, Kumasi, Ghana, September 16–20, 2013, "Pandemic and seasonal influenza update."

37. Ghana College of Physicians and Surgeons Medical Knowledge Fiesta 2013, Golden Tulip Hotel, Kumasi, Ghana, September 16–20, 2013, “HIV and tuberculosis co-infection update.”
38. Infectious Diseases Lecture Series, The Miriam Hospital, Providence, RI, July 30, 2015, “Tuberculosis.”
39. University of Florida, Gainesville, FL. November 16, 2015. “Challenges to optimized TB and HIV coinfection treatment in resource-limited settings”.
40. The 46th Union World Conference on Lung Health, Cape Town, South Africa. December 6, 2015. *Symposium 54: Critical updates on the treatment on the treatment of TB-HIV co-infected children.* “Pharmacokinetics of the first-line TB drugs in West Africa children with and without HIV co-infection”.

CURRENT GRANTS

NIH/NICHD (Kwara, PI) 7/15/12-4/30/18 6 cal. months
 1 R01HD071779 \$466,240 (direct)
 Title: Pharmacokinetics of anti-tuberculosis and antiretroviral drugs in children

The goal of this grant is develop a long-term program to study the pharmacokinetics and pharmacogenetics of HIV therapy in children at the Komfo Anokye Teaching Hospital, Kumasi, Ghana.

Role: Principal Investigator

NIH/FIC (Kwara, PI) 6/15/15-5/31/20 1.8 cal. months
 1D43TW010055-01 \$274,965 (direct)
 Title: Training Program in Tuberculosis and HIV Research in Ghana

The major goals of this project are to train Ghanaian graduate and post-graduate physicians and scientists in tuberculosis and HIV research.

Role: Principal Investigator

NIH/NIAID (Cu-Uvin, PI) 5/1/15-4/30/16 0.35 calendar
 5-P30 AI42853 \$161,279
 Title: Efficacy of Oxazolidinones alone in *in vitro* EBA studies & in polydrug TB therapy

The major goal is to evaluate is evaluating the relative toxicities of linezolid, sutezolid and AZD5847 in *in vitro* tests

Role: Co-I Investigator

COMPLETED GRANTS

USAID (Flanigan, PI) 7/1/11-6/30/13 1.2 cal. months
 Award # AEG-A-00-05-00007 \$1,100,000
 University of Ghana/Brown University Academic Partnership to Address HIV/AIDS in Ghana.

The goal of this grant is to build capacity of the University of Ghana to conduct research, train and provide community service that contributes to enhanced response to the challenges of HIV/AIDS in Ghana.

Role: Co-Principal Investigator

European and Development Countries Clinical Trials Partnership (EDCTP)

Professor C.S. Mgone (PI) 7/7/2010 – 7/6/2013

Title: Capacity building to prepare West African sites for clinical trials on HIV, TB and malaria.

The goal of this grant is to set up nodes of excellence in HIV, TB and malaria research in West Africa.

Role: Co-Investigator, Korle-Bu Teaching Hospital Site, Accra, Ghana.

NIH/NAID (PI) 6/1/11-8/31/12 3.24 cal. months

1 R56 AI091448 \$487,804

Title: Pharmacogenetics and Drug-to-Drug Interactions during HIV/TB Therapy

The goal of this grant is to develop and validate an *in vitro* model for studying drug-drug and drug-gene interactions between TB and HIV drugs.

Role: Principal Investigator

NIH/NAID (PI) 8/1/06-6/30/11 50% Effort

1K23AI071760-01 \$634,770

Mentored Career Developmental Award

Title: Concurrent HAART and Tuberculosis Treatment: Drug to Drug Interactions

The goal of this grant is to support the training of Dr Awewura Kwara in clinical research related to pharmacokinetics of HIV and TB therapies through a Mentored Patient-Oriented Research Career Developmental Award (K23).

Role: Principal Investigator

5-P30 AI42853-07

Carpenter (PI) 12/1/04-11/30/05

Lifespan/Tufts/Brown Center for AIDS Research

Developmental Award

Title: Pharmacokinetics and Virologic Response to Efavirenz-based Antiretroviral Therapy in HIV/TB co-infected Patients Receiving Rifampin-based TB Treatment in sub-Saharan Africa.

The goal of this study is to determine whether the drug-drug interactions between rifampin and efavirenz is clinically significant in HIV/TB co-infected patients in sub-Saharan Africa.

Role: Principal Investigator

Doris Duke Foundation AIDS Care Research in Africa Award Lartey (PI) 01/06-12/07

Title: Comparison of Responses to Antiretroviral Therapy in HIV-infected Adults with and without Tuberculosis coinfection: Is Outcomes different?

The goal of this study is to compare the efficacy and tolerability of a once daily antiretroviral regimen consisting of lamivudine, didanosine and efavirenz in HIV/TB co-infected and HIV mono-infected patients in Ghana.

Role: Co-Investigator

USAID Higher Education for Development Wing (PI) 11/1/09 – 3/31/2010
Title: Brown University/University of Ghana College of Health Sciences Higher Education Initiative for HIV/AIDS.

The planning grant enabled the partner universities develop and submit a long-term strategic plan for HIV/AIDS initiative.

Role: Co-Investigator

UNIVERSITY TEACHING ROLES

| | |
|--------------|--|
| 2007-present | Preceptor/mentor for summer research projects. Scholarly Concentration in Global Health. One-two medical students per year. |
| 2007-2009 | Lecturer, "Helmithises," Introduction to Tropical Medicine Lecturer. |
| 2008-2009 | Lecturer, "HIV and Tuberculosis Research at Korle-Bu Teaching Hospital, Ghana" Global Health and Medicine Lectures Series. |
| 2009 | Lecturer, "HIV and Tuberculosis Research at Korle-Bu Teaching Hospital, Ghana" Global Health and Medicine Lectures Series. |
| 2009 | Lecturer, "Staying Healthy While Traveling Abroad," Scholarly Concentration on Global Health, Brown University. |
| 2009-14 | Lecturer, "Tuberculosis." Burden of Diseases in Developing Countries (PHP 1070), Brown University. |
| 2014-15 | Lecturer, "Double Trouble: The problem of TB and HIV coinfection." HIV/AIDS in Africa: A Multidisciplinary Approach to Support, HIV/AIDS Care and Treatment Programs (PHP 1400), Brown University. |
| 2014 | Lecturer, "Global Epidemiology of Tuberculosis," Infectious Diseases Epidemiology (PHP 1845), Brown University. |
| 2015 | Lecturer, Building capacity for HIV and TB/HIV care and research in Ghana. Local and global community engagement to reduce health disparities (PHP 2385), Brown University. |
| 2014-15 | Faculty, Independent study for seniors (BIOL 1960). Students: Adriana Saavedra and Nia Campinha-Bacote. Topic: Characteristics and predictors of early mortality of HIV-infected adults admitted to Korle-bu Teaching Hospital ward. |
| 2015 | Lecturer, "Global Epidemiology of Tuberculosis," Infectious Diseases Epidemiology (PHP 1845), Brown University. |

2015 Lecturer, "Tuberculosis." Burden of Diseases in Developing Countries (PHP 1070), Brown University.

HOSPITAL TEACHING ROLES

2005-present Preceptor for Infectious Diseases Fellows, Longitudinal Infectious Diseases Ambulatory Clinic, The Miriam Hospital

2009 Small group leader, Pathophysiology Course, Fungal Infection. Second year medical students, Rhode Island Hospital/The Miriam Hospital

2009 Lecturer, "Tuberculosis and other Mycobacterial infections," Rhode Island Hospital Internal Medicine Residents noon conference series.

2013 Lecturer, "Tuberculosis and other Mycobacterial infections," The Miriam Hospital Internal Medicine Residents noon conference series.

2015 Lecturer, "Tuberculosis Case Conference," Infectious Diseases Case Conference series.